Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Two Considerations - 80% of Revenue going to TPL - badger
24
Mar 24, 2010 11:58AM
8
Mar 24, 2010 12:50PM
1
Mar 24, 2010 01:05PM
3
Mar 24, 2010 01:43PM
2
Mar 24, 2010 01:56PM
4
Mar 24, 2010 04:10PM
1
Mar 24, 2010 04:36PM

I respectfully request you read my post of 1:43pm today. IMO, it's not necessarily TPL that's currently getting the 80% of MMP revenues, it's Alliacense. The money that goes to PDS is for distribution to the owners of the rights to the patents, PTSC and TPL. Money withheld from PDS is NOT being distributed. It's being consumed by the multi-facetted, essential Alliacense activities.

With regard to Gloria's review of Alliacense accounting: You think she's not competent to perform such action? You think she doesn't have a vested interest in accounting accuracy? Your "non-sense" comment suggests you believe the answers to these questions to be "no". Why do you believe such?

JMHO,

SGE

5
Mar 24, 2010 05:52PM
2
Mar 24, 2010 06:21PM
6
Mar 24, 2010 07:02PM
1
Mar 24, 2010 08:21PM
Share
New Message
Please login to post a reply